Division of Roche
Latest From BioImagene Inc.
Noteworthy news from medtech start-ups. This month we profile Ibris, which is developing prognostics to identify breast cancer patients in need of chemotherapy, and Delphinus Medical Technologies, whose platform enables 3-D full breast ultrasound.
Patients with aggressive estrogen receptor-positive breast cancer need chemotherapy in addition to treatment with anti-estrogen therapies. The question for physicians: how to determine how aggressive a cancer is going to be? Ibris Inc. is working to provide that information with a rapid, predictive, prognostic test that can identify ER-positive breast cancer patients requiring chemotherapy.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Senior Management
Ajit Singh, PhD, CEO
Vivek Pathak, CFO
Steve Barbee, VP, Sales
Robert Monroe, MD, PhD, CMO
- Contact Info
Phone: (408) 207-4200
919 Hermosa Ct.
Sunnyvale, CA 94085
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.